nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study
|
Shepherd, James |
|
2001 |
87 |
5S1 |
p. 19-22 4 p. |
artikel |
2 |
Introduction
|
Gotto Jr., Antonio M. |
|
2001 |
87 |
5S1 |
p. 1- 1 p. |
artikel |
3 |
Novel approaches to lipid lowering: what is on the horizon?
|
Brown, W.Virgil |
|
2001 |
87 |
5S1 |
p. 23-27 5 p. |
artikel |
4 |
Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor 1 1 CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
|
McTaggart, Fergus |
|
2001 |
87 |
5S1 |
p. 28-32 5 p. |
artikel |
5 |
Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management∗ ∗ This article represents one side of a debate on the role of lipid subfractions in cardiovascular risk management; the opposing argument can be found in the accompanying article by Terje R. Pedersen, MD, PhD.
|
Assmann, Gerd |
|
2001 |
87 |
5S1 |
p. 2-7 6 p. |
artikel |
6 |
Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management∗ ∗ This article represents one side of a debate regarding the role of lipid subfractions in cardiovascular risk management; the opposing argument can be found in the accompanying article by Gerd Assmann, MD.
|
Pedersen, Terje R |
|
2001 |
87 |
5S1 |
p. 8-12 5 p. |
artikel |
7 |
Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin 1 1 CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
|
Olsson, Anders G |
|
2001 |
87 |
5S1 |
p. 33-36 4 p. |
artikel |
8 |
Statin therapy: where are we? where do we go next?
|
Gotto Jr., Antonio M |
|
2001 |
87 |
5S1 |
p. 13-18 6 p. |
artikel |